Technical Analysis for BNTC - Benitec Biopharma Limited

Grade Last Price % Change Price Change
grade D 0.82 -10.87% -0.10
BNTC closed down 10.87 percent on Wednesday, September 18, 2019, on 3.04 times normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical BNTC trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Volume Surge Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish -10.87%
Crossed Above 50 DMA Bullish -10.87%
MACD Bullish Signal Line Cross Bullish -10.87%
New Uptrend Bullish -10.87%
Expansion Pivot Buy Setup Bullish Swing Setup -10.87%

Older signals for BNTC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Biotechnology Biopharmaceutical Biology Pain Chemotherapy Genetics Gene Expression Genetic Engineering Hepatitis B HIV/Aids Wet Age Related Macular Degeneration Huntington's Disease RNA Retinitis Pigmentosa Hepatitis C Clinical Applications Oculopharyngeal Muscular Dystrophy Chronic And Life Threatening Conditions
Is BNTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.0
52 Week Low 0.5
Average Volume 62,224
200-Day Moving Average 1.4618
50-Day Moving Average 0.7136
20-Day Moving Average 0.6891
10-Day Moving Average 0.6723
Average True Range 0.1105
ADX 29.65
+DI 49.3307
-DI 15.1827
Chandelier Exit (Long, 3 ATRs ) 0.9885
Chandelier Exit (Short, 3 ATRs ) 0.8715
Upper Bollinger Band 0.8443
Lower Bollinger Band 0.5339
Percent B (%b) 0.92
BandWidth 45.044261
MACD Line -0.0042
MACD Signal Line -0.0263
MACD Histogram 0.0221
Fundamentals Value
Market Cap 8.41 Million
Num Shares 10.3 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -1.58
Price-to-Sales 3.15
Price-to-Book 1.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.15
Resistance 3 (R3) 1.15 1.03 1.10
Resistance 2 (R2) 1.03 0.95 1.04 1.08
Resistance 1 (R1) 0.93 0.90 0.87 0.93 1.06
Pivot Point 0.81 0.81 0.79 0.82 0.81
Support 1 (S1) 0.71 0.73 0.65 0.71 0.58
Support 2 (S2) 0.59 0.68 0.60 0.56
Support 3 (S3) 0.49 0.59 0.55
Support 4 (S4) 0.49